Publications database

Latest additions:
2026-02-27
15:33
[DKFZ-2026-00477] Journal Article
; ; ; et al
Multiplexed biomarkers dynamically detect heterogeneous residual neuroblastoma cell clone activity in the bone marrow niche.
Monitoring MYCN-driven high-risk neuroblastoma presents challenges to capture dynamics of all tumor cell clones at their earliest divergence to current clinical course. Not all clones may enter the bone marrow, the most important monitoring site for minimal residual disease (MRD), causing relapse in ∼50% of patients. [...]

Detailed record - Similar records
2026-02-27
15:30
[DKFZ-2026-00476] Journal Article (Review Article)
; ; ; et al
Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck. [Neue theranostische Zielstrukturen bei Plattenepithelkarzinomen von Kopf und Hals].
This review aims to explore the evolving field of theranostics in oncology, focusing on its potential application to head and neck squamous cell carcinoma (HNSCC). Specifically, it examines the integration of molecular imaging and radionuclide therapy in the context of theranostics.A comprehensive review of current literature was conducted to evaluate the state-of-the-art theranostic approaches in HNSCC. [...]

Detailed record - Similar records
2026-02-27
15:29
DBCoverage [DKFZ-2026-00475] Journal Article
; ; ; et al
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study.
The MORPHEUS platform comprised multiple open-label, randomized, phase Ib/II trials to identify early signals with different treatment combinations across multiple cancers. MORPHEUS-PDAC (NCT03193190) evaluated atezolizumab combinations in pancreatic ductal adenocarcinoma (PDAC). [...]

Detailed record - Similar records
2026-02-27
15:27
DBCoverage [DKFZ-2026-00474] Journal Article
; ; ; et al
Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.
Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signaling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma (NB), in keeping with its role in RS resistance. [...]

Detailed record - Similar records
2026-02-27
15:24
[DKFZ-2026-00473] Journal Article
; ; ; et al
A disease model resource reveals core principles of tissue-specific cancer evolution.
Oncogenes such as KRAS display marked tissue specificity in their oncogenic potential, genetic interactions and phenotypic effects, but the underlying determinants remain largely unresolved1-5. Here, to address these questions, we developed the Mouse Cancer Cell line Atlas, a broad-utility resource of 590 comprehensively characterized models across a wide range of entities ( www.mcca.tum.de ). [...]

Detailed record - Similar records
2026-02-27
15:17
[DKFZ-2026-00472] Journal Article
; ; ; et al
Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer.
Advanced breast cancer is associated with the development of brain metastases in 20%-40% of patients. Differential post-radiotherapy recurrence patterns depending on hormone receptor (HR) and human epidermal growth receptor 2 (HER2) status have been reported. [...]

Detailed record - Similar records
2026-02-27
15:11
DBCoverage [DKFZ-2026-00471] Journal Article
; ; ; et al
A translational colorectal cancer organoid biobank mirrors patients' tumor histology, molecular profiles, and treatment responses.
Colorectal cancer (CRC) exhibits pronounced inter- and intratumoral heterogeneity, emphasizing the need for preclinical models that accurately capture its molecular and histological diversity. Patient-derived organoids (PDOs) represent valuable ex vivo systems to model CRC, yet whether they can preserve subtype-specific features and maintain fidelity upon in vivo transplantation remains unclear.We established a biobank of PDOs from both treatment-naïve and neoadjuvant-treated CRC patients, encompassing the major histological subtypes - micropapillary, medullary, serrated, mucinous, and adenocarcinoma not otherwise specified (NOS). [...]

Detailed record - Similar records
2026-02-27
15:08
DBCoverage [DKFZ-2026-00470] Journal Article
; ; ; et al
Reporting checklist for foundation and large language models in medical research (REFINE): an international consensus guideline.
To develop the REporting checklist for FoundatIon and large laNguagE models (REFINE), an international reporting guideline for transparent and reproducible reporting of foundation model (FM) and large language model (LLM) studies in medical research, including imaging artificial intelligence (AI) applications.The protocol was prespecified and publicly archived. A modified Delphi process was conducted to establish reporting standards for unimodal and multimodal FM and LLM applications involving text, imaging, and structured data. [...]

Detailed record - Similar records
2026-02-27
15:06
DBCoverage [DKFZ-2026-00469] Journal Article
; ; ; et al
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis.
In relapsed/refractory classic Hodgkin lymphoma (r/r cHL), salvage followed by high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT) yields suboptimal outcomes. PD-1 inhibitor-based salvage regimens have shown superior complete response (CR) rates of up to 95% (for P-GVD) with unprecedented PFS after HD-ASCT. [...]

Detailed record - Similar records
2026-02-27
15:04

Detailed record - Similar records